Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/66416
Title: Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy.
Author: Roca, Isart
Requena, Jordi
Edel, Michael John
Alvarez Palomo, Ana Belen
Keywords: Cèl·lules mare
Múscul estriat
Distròfia muscular
Teràpia cel·lular
Stem cells
Striated muscle
Muscular dystrophy
Cellular therapy
Issue Date: 29-Jan-2015
Publisher: MDPI
Abstract: The use of adult myogenic stem cells as a cell therapy for skeletal muscle regeneration has been attempted for decades, with only moderate success. Myogenic progenitors (MP) made from induced pluripotent stem cells (iPSCs) are promising candidates for stem cell therapy to regenerate skeletal muscle since they allow allogenic transplantation, can be produced in large quantities, and, as compared to adult myoblasts, present more embryonic-like features and more proliferative capacity in vitro, which indicates a potential for more self-renewal and regenerative capacity in vivo. Different approaches have been described to make myogenic progenitors either by gene overexpression or by directed differentiation through culture conditions, and several myopathies have already been modeled using iPSC-MP. However, even though results in animal models have shown improvement from previous work with isolated adult myoblasts, major challenges regarding host response have to be addressed and clinically relevant transplantation protocols are lacking. Despite these challenges we are closer than we think to bringing iPSC-MP towards clinical use for treating human muscle disease and sporting injuries.
Note: Reproducció del document publicat a: http://dx.doi.org/10.3390/jcm4020243
It is part of: Journal of Clinical Medicine, 2015, vol. 4, num. 2, p. 243-259
Related resource: http://dx.doi.org/10.3390/jcm4020243
URI: http://hdl.handle.net/2445/66416
ISSN: 2077-0383
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
650729.pdf142.92 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons